Maze Therapeutics (NASDAQ:MAZE) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) saw strong trading volume on Tuesday . 967,495 shares traded hands during mid-day trading, an increase of 35% from the previous session’s volume of 717,528 shares.The stock last traded at $27.92 and had previously closed at $27.42.

Analyst Ratings Changes

Several analysts have commented on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 31st. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Mizuho raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 11th. HC Wainwright boosted their price target on shares of Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, March 25th. Finally, Lifesci Capital raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $66.00.

Maze Therapeutics Stock Up 4.5%

The firm’s 50-day moving average price is $42.11 and its 200-day moving average price is $38.25. The company has a market cap of $1.42 billion, a P/E ratio of -8.79 and a beta of 5.16.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Wednesday, March 25th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.08.

Insider Activity

In related news, SVP Amy Bachrodt sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $29.44, for a total transaction of $73,600.00. Following the sale, the senior vice president owned 12,965 shares of the company’s stock, valued at approximately $381,689.60. This represents a 16.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction that occurred on Thursday, January 29th. The stock was sold at an average price of $44.27, for a total transaction of $332,025.00. Following the sale, the insider directly owned 10,503 shares in the company, valued at $464,967.81. This trade represents a 41.66% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 95,000 shares of company stock valued at $4,245,625 over the last quarter.

Institutional Trading of Maze Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of Canada increased its holdings in Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after acquiring an additional 363 shares during the period. GF Fund Management CO. LTD. bought a new stake in Maze Therapeutics during the 4th quarter worth approximately $39,000. Caitong International Asset Management Co. Ltd bought a new stake in Maze Therapeutics during the 4th quarter worth approximately $43,000. California State Teachers Retirement System increased its holdings in Maze Therapeutics by 138.0% during the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock worth $55,000 after acquiring an additional 766 shares during the period. Finally, Ameritas Investment Partners Inc. increased its holdings in Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after acquiring an additional 738 shares during the period.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.